A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults

Who can take part

Eligibility criteria for randomisation Inclusion Criteria: * Aged 18 to 40 years (inclusive) * Body mass index (BMI) ≥27 kg/m2 * Clinical diagnosis of primary (essential) hypertension as per NICE guidance * Unattended brachial SBP ≥135 and/or DBP ≥85 mmHg and \<160/100 mmHg * Maximum of one antihypertensive medication Exclusion Criteria: • Anything in medical notes suggesting unsuitable in the opinion of the investigator Eligibility criteria for participation in weight loss arm Inclusion criteria: * Written informed consent * Aged 18 to 40 years (inclusive) * Body mass index ≥27 kg/m2 * Clinical diagnosis of primary (essential) hypertension as per NICE guidance * Unattended brachial SBP ≥135 and/or DBP ≥85 mmHg and \<160/100 mmHg * Maximum of one antihypertensive medication Exclusion criteria: The presence of any of the following will preclude participant inclusion: * Known or suspected secondary hypertension * Hypersensitivity to any of the study drugs or excipients * Currently taking drugs likely to have interactions with tirzepatide * Diagnosis of type 1 or type 2 diabetes mellitus or current usage of insulin or other injectable drugs for the treatment of diabetes such as but not limited to GLP-1 and GIP receptor agonists * Prior or planned surgical, endoscopic and/or device-based therapy treatment for obesity * Self-reported, intentional or unintentional, change in body weight (over \~10%) within \~three months of screening * Known heart failure or clinically significant valvular heart disease * Implanted pacemaker or implantable cardioverter defibrillator (ICD) * Second or third-degree AV block, sino-atrial block, sick sinus syndrome * Known active malignancy including thyroid cancer * Known renal impairment (creatinine \>150µmol/L) * Clinically significant neurological disease * History of scleroderma * Participants on anticoagulant therapy * Known history of pancreatitis * Known inflammatory bowel disease * History of gallstones (unless previous cholecystectomy) * Severe gastroparesis or gastric emptying abnormality * Family history of multiple endocrine neoplasia * Needle-phobia * Planned pregnancy, current pregnancy, or breastfeeding * Current involvement in the active treatment phase of other research studies * Any other clinical reason which may preclude entry in the opinion of the investigator

Registry changes

No changes recorded since the trial was added.